Tag Archives: cell-based cancer immunotherapy

October, 2016

  • 3 October

    Bluebird Bio and Medigene Enter $1 Billion+ Cancer Immunotherapy Deal

    MARTINSRIED/MUNICH & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, and bluebird bio, Inc. (Nasdaq: BLUE), USA, today announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies against four targets. “We are delighted to collaborate with bluebird bio, a …

March, 2015